cancer proliferation attenuation by suppression of glypican-1 and pleiotropic effects | oncotarget
Published 1 year ago • 55 plays • Length 2:16Download video MP4
Download video MP3
Similar videos
-
4:32
behind the study: dll3, asc1, ttf-1 & ki-67 in precision medicine for sclc | oncotarget
-
10:09
diagnosis, staging, and prognosis
-
0:16
activated t cell attacks a cancer cell
-
1:22
dr. glaspy on immunogenicity in ovarian cancer
-
0:54
parp inhibitors advance beyond treatment of brca1/2-mutant gynecologic cancers
-
1:51
brca and rab: prognostic biomarkers in recurrent ovarian cancer
-
1:24
kd033, a pdl1-1l15 bispecific molecule for the treatment of cancer
-
6:25
moving forward: the critical importance of high-quality biospecimens in cancer research
-
3:45
parp inhibitors gbrca1/2-mutated pancreatic cancer
-
2:10
proclipi: registry & establishment of a prognostic index for mf and ss
-
0:49
st101: targeting c/ebpβ in patients with advanced solid tumors
-
5:02
prognostic value of brafv600 mutations in stage 3 cutaneous melanoma patients
-
59:26
targeting cancer pathways: tumor metabolism and proliferation
-
3:16
clinical characteristics and prognostic factors of plasmablastic lymphoma patients
-
2:09
the promise of csf and pet biomarkers in caa
-
21:19
repeat biopsies & emerging technologies for plasma sampling of mutations
-
6:58
detecting somatic brca1/2 mutations in ovarian cancer
-
1:58
discussing targeted treatment with parp inhibitors for brca-mutant patients across tumor types
-
1:02:21
wholistic!™ - biopsy, biomarkers and brain donation - dr. charles adler